Former President of AstraZeneca India joins Innate Pharmaceuticals ...

lunchlexicographerΒιοτεχνολογία

1 Δεκ 2012 (πριν από 4 χρόνια και 6 μήνες)

273 εμφανίσεις


PRESSMEDDELANDE

__________________________________________________________________________________________


2008-09-24


Former President of AstraZeneca India joins Innate
Pharmaceuticals Board

The Nomination Committee of Innate Pharmaceuticals is proposing that
Kumud Sampath and Ingemar Kihlström join the company’s Board. They
both have many years of experience of operational activity in the
pharmaceutical and biotechnology industries.


Innate Pharmaceuticals has acquired fundamental knowledge of the effects of virulence blockers on
bacteria in several disease areas through cooperation with leading academic research teams in
Europe and the United States. This knowledge base will now be utilised to develop medicines and
seek partners for product and market development.

It is proposed that the Board be strengthened by the addition of two new directors in the new phase
the company is now entering.

Kumud Sampath, who was born in 1958, was born and raised in India, and was trained in
management at International Management Development (IMD) in Switzerland. She has a long
career behind her in Astra and AstraZeneca in Bangalore in India and was President of
AstraZeneca India from 2000 to 2005. She was then Vice-President, International of United States
Pharmacopoeia India.

Innate’s research and clinical activities in India will steadily increase through the cooperation
agreement with Syngene International in Bangalore. The participation of Kumud Sampath in the
Board's work gives it unique opportunities to monitor developments independently.

Ingemar Kihlström, who was born in 1952, has worked as a research scientist at Uppsala University
and in the pharmaceutical companies Astra and Pharmacia. He has worked as a toxicologist and
been responsible for evaluating the safety of candidate drugs. He has also worked as a
pharmaceutical analyst. He is now strategic advisor in Life Science and a director of several
biotechnology companies, such as Artimplant AB and Medivir AB.

The current Board members Peter Sjöstrand, Hans Sievertsson and Kjell Strandberg have decided
not to stand for re-election.

The Annual General Meeting of Innate Pharmaceuticals will be held on 30 October 2008 in Umeå.


For further information, please contact Sune Rosell, MD, CEO of Innate Pharmaceuticals AB, by
telephone on +46 (0)90-13 66 50 or +46 (0)70-557 22 00. E-mail: info@innate.se
. Website:
www.innate.se
.


Innate Pharmaceuticals AB (publ) was formed in 2000 to commercialise world-leading research at
Umeå University and Karolinska Institutet in Stockholm. The company has developed and applied for
patent protection for a number of chemical substances used to treat bacterial infections, known as
virulence blockers. These substances block the ability of certain bacteria to cause disease without
destroying them. If bacteria are disarmed in this way instead of being destroyed, the risk of bacteria
developing resistance to drugs is reduced.